<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Melanoma | The Miller Lab</title>
    <link>/tags/melanoma/</link>
      <atom:link href="/tags/melanoma/index.xml" rel="self" type="application/rss+xml" />
    <description>Melanoma</description>
    <generator>Source Themes Academic (https://sourcethemes.com/academic/)</generator><language>en-us</language><lastBuildDate>Sat, 18 Jan 2020 11:00:00 +0000</lastBuildDate>
    <image>
      <url>/img/MLab_logo_5.png</url>
      <title>Melanoma</title>
      <link>/tags/melanoma/</link>
    </image>
    
    <item>
      <title>Therapeutic Updates in Melanoma - IO for Earlier Stage Disease</title>
      <link>/talk/odac_melanoma-1-18-20/</link>
      <pubDate>Sat, 18 Jan 2020 11:00:00 +0000</pubDate>
      <guid>/talk/odac_melanoma-1-18-20/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Melanoma - Pathogenesis, Clinical Features, Diagnosis and Management</title>
      <link>/talk/cumc_derm_lecture_melanoma-12-13-19/</link>
      <pubDate>Fri, 13 Dec 2019 09:00:00 +0000</pubDate>
      <guid>/talk/cumc_derm_lecture_melanoma-12-13-19/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Melanoma - Pathogenesis, Diagnosis and Work Up</title>
      <link>/slides/melanoma_12_13_19-final-ppt/</link>
      <pubDate>Wed, 11 Dec 2019 09:00:00 +0000</pubDate>
      <guid>/slides/melanoma_12_13_19-final-ppt/</guid>
      <description>


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Intro-Slide.jpg&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Disclosures.jpg&#34;
  &gt;


&lt;hr /&gt;

&lt;h2 id=&#34;learning-objectives&#34;&gt;Learning Objectives&lt;/h2&gt;

&lt;ul&gt;
&lt;li&gt;Review basic epidemiology of melanoma&lt;/li&gt;
&lt;li&gt;Review molecular mechanisms of melanoma&lt;/li&gt;
&lt;li&gt;Discuss risk factors for melanoma&lt;/li&gt;
&lt;li&gt;Review how to evaluate and stage patients&lt;/li&gt;
&lt;li&gt;Overview of management of melanoma&lt;/li&gt;
&lt;/ul&gt;

&lt;hr /&gt;

&lt;h2 id=&#34;pre-lecture-quiz&#34;&gt;Pre-Lecture Quiz&lt;/h2&gt;

&lt;ul&gt;
&lt;li&gt;Take out your cell phone&lt;/li&gt;
&lt;li&gt;Open text message app&lt;/li&gt;
&lt;li&gt;Follow the instructions on the screen&lt;/li&gt;
&lt;/ul&gt;

&lt;hr /&gt;

&lt;h2 id=&#34;epidemiology&#34;&gt;Epidemiology&lt;/h2&gt;

&lt;ul&gt;
&lt;li&gt;1:25 Americans will get some kind of melanoma in their lifetime&lt;/li&gt;
&lt;li&gt;1:52 Americans will get an invasive melanoma in their lifetime&lt;/li&gt;
&lt;li&gt;Estimated to be 96,480 newly diagnosed cases of invasive melanoma in the U.S. in 2019

&lt;ul&gt;
&lt;li&gt;95,830 cases of melanoma in situ&lt;/li&gt;
&lt;/ul&gt;&lt;/li&gt;
&lt;li&gt;Between 9,000-10,000 deaths annually&lt;/li&gt;
&lt;/ul&gt;

&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/ACS-Cancer-Stats.jpg&#34;
  &gt;


&lt;hr /&gt;

&lt;h2 id=&#34;hallmarks-of-cancer&#34;&gt;Hallmarks of Cancer&lt;/h2&gt;

&lt;ul&gt;
&lt;li&gt;Self-sufficiency of growth signals&lt;/li&gt;
&lt;li&gt;Insensitivity to anti-growth signals&lt;/li&gt;
&lt;li&gt;Evading apoptosis&lt;/li&gt;
&lt;li&gt;Limitless replicative potential&lt;/li&gt;
&lt;li&gt;Sustained angiogenesis&lt;/li&gt;
&lt;li&gt;Tissue invasion and metastasis&lt;br /&gt;&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Ref: Hanahan and Weinberg. &lt;em&gt;Cell&lt;/em&gt; 2000. Vol 100&lt;/p&gt;

&lt;hr /&gt;

&lt;h3 id=&#34;hallmarks-of-cancer-updated&#34;&gt;Hallmarks of Cancer - Updated&lt;/h3&gt;

&lt;ul&gt;
&lt;li&gt;Deregulating Cellular Energetics&lt;/li&gt;
&lt;li&gt;Genome Instability and Mutation&lt;/li&gt;
&lt;li&gt;Avoiding Immune Destruction&lt;/li&gt;
&lt;li&gt;Tumor-promoting Inflammation&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Ref: Hanahan and Weinberg. &lt;em&gt;Cell&lt;/em&gt; 2011.&lt;/p&gt;

&lt;hr /&gt;

&lt;h2 id=&#34;melanoma-pathogenesis&#34;&gt;Melanoma Pathogenesis&lt;/h2&gt;

&lt;hr /&gt;

&lt;h3 id=&#34;oncogenes-and-tumor-suppressors&#34;&gt;Oncogenes and Tumor Suppressors&lt;/h3&gt;

&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Oncogenes-tsgs.jpg&#34;
  &gt;


&lt;hr /&gt;

&lt;h2 id=&#34;oncogenes-in-melanoma&#34;&gt;Oncogenes in Melanoma&lt;/h2&gt;

&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Oncogenes-in-melanoma.jpg&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/cell-cycle.jpg&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/legend-cell-cycle.jpg&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/senescence.jpg&#34;
  &gt;


&lt;h4 id=&#34;oncogene-induced-senescence&#34;&gt;Oncogene-Induced Senescence&lt;/h4&gt;

&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/legend-senescence.jpg&#34;
  &gt;


&lt;hr /&gt;

&lt;h2 id=&#34;why-don-t-all-melanocytes-undergo-oncogene-induced-senescence&#34;&gt;Why don’t all melanocytes undergo oncogene-induced senescence?&lt;/h2&gt;

&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/cell-cycle-2.jpg&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/melanoma-pathways.jpg&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/melanoma-pathways-legend.jpg&#34;
  &gt;


&lt;hr /&gt;

&lt;h3 id=&#34;susceptibility-to-cutaneous-malignant-melanoma-cmm&#34;&gt;Susceptibility to Cutaneous Malignant Melanoma (CMM)&lt;/h3&gt;

&lt;ul&gt;
&lt;li&gt;CMM1 has been mapped to chromosome 1p36.&lt;/li&gt;
&lt;li&gt;CMM2 – CDKN2A (9p21)&lt;/li&gt;
&lt;li&gt;CMM3 – CDK4 (12q14)&lt;/li&gt;
&lt;li&gt;CMM4 – mapped to chromosome 1p22&lt;/li&gt;
&lt;li&gt;CMM5 – MC1R (16q24)&lt;/li&gt;
&lt;li&gt;CMM6 – XRCC3 (14q32)&lt;/li&gt;
&lt;li&gt;CMM7 – mapped to chromosome 20q11&lt;/li&gt;
&lt;li&gt;CMM8 – MITF (3p13)&lt;/li&gt;
&lt;li&gt;CMM9 – TERT (5p15)&lt;/li&gt;
&lt;li&gt;CMM10 – POT1 (7q31)&lt;/li&gt;
&lt;/ul&gt;

&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/CDKN2A.jpg&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Prognosis.jpg&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Tx-strategies.jpg&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Approved-Tx.jpg&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/CIT.jpg&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Legend-CIT.jpg&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Stage-3-Tx.jpg&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Tx-Metastatic-Dz.jpg&#34;
  &gt;


&lt;hr /&gt;
</description>
    </item>
    
    <item>
      <title>Therapeutic Updates in Melanoma - IO for Earlier Stage Disease</title>
      <link>/slides/odac_melanoma-1-18-20/</link>
      <pubDate>Mon, 09 Dec 2019 00:00:00 +0000</pubDate>
      <guid>/slides/odac_melanoma-1-18-20/</guid>
      <description>
&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Intro-Slide.jpg&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Disclosures.jpg&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Learning-Objectives.jpg&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Melanoma-Approvals.jpg&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Targeted-Therapy.jpg&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Immune-Checkpoints.jpg&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Melanoma-Approvals-Color.jpg&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Acknowledgements.jpg&#34;
  &gt;


&lt;hr /&gt;
</description>
    </item>
    
    <item>
      <title>Primer - Melanoma - Pathogenesis, Diagnosis and Work Up</title>
      <link>/slides/melanoma_12_13_19-primer/</link>
      <pubDate>Sun, 08 Dec 2019 00:00:00 +0000</pubDate>
      <guid>/slides/melanoma_12_13_19-primer/</guid>
      <description>


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Intro-Slide.jpg&#34;
  &gt;


&lt;hr /&gt;

&lt;h2 id=&#34;learning-objectives&#34;&gt;Learning Objectives&lt;/h2&gt;

&lt;ul&gt;
&lt;li&gt;Review basic epidemiology of melanoma&lt;/li&gt;
&lt;li&gt;Review molecular mechanisms of melanoma&lt;/li&gt;
&lt;li&gt;Discuss risk factors for melanoma&lt;/li&gt;
&lt;li&gt;Review how to evaluate and stage patients&lt;/li&gt;
&lt;li&gt;Overview of management of melanoma&lt;/li&gt;
&lt;/ul&gt;

&lt;hr /&gt;

&lt;h2 id=&#34;epidemiology&#34;&gt;Epidemiology&lt;/h2&gt;

&lt;ul&gt;
&lt;li&gt;1:25 Americans will get some kind of melanoma in their lifetime&lt;/li&gt;
&lt;li&gt;1:52 Americans will get an invasive melanoma in their lifetime&lt;/li&gt;
&lt;li&gt;Estimated to be 96,480 newly diagnosed cases of invasive melanoma in the U.S. in 2019

&lt;ul&gt;
&lt;li&gt;95,830 cases of melanoma in situ&lt;/li&gt;
&lt;/ul&gt;&lt;/li&gt;
&lt;li&gt;Between 9,000-10,000 deaths annually&lt;/li&gt;
&lt;/ul&gt;

&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/ACS-Cancer-Stats.jpg&#34;
  &gt;


&lt;hr /&gt;

&lt;h2 id=&#34;melanoma-pathogenesis&#34;&gt;Melanoma Pathogenesis&lt;/h2&gt;

&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/melanoma-pathways.jpg&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/melanoma-pathways-legend.jpg&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/cell-cycle.jpg&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/legend-cell-cycle.jpg&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/senescence.jpg&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/legend-senescence.jpg&#34;
  &gt;


&lt;hr /&gt;

&lt;h3 id=&#34;susceptibility-to-cutaneous-malignant-melanoma-cmm&#34;&gt;Susceptibility to Cutaneous Malignant Melanoma (CMM)&lt;/h3&gt;

&lt;ul&gt;
&lt;li&gt;CMM1 has been mapped to chromosome 1p36.&lt;/li&gt;
&lt;li&gt;CMM2 – CDKN2A (9p21)&lt;/li&gt;
&lt;li&gt;CMM3 – CDK4 (12q14)&lt;/li&gt;
&lt;li&gt;CMM4 – mapped to chromosome 1p22&lt;/li&gt;
&lt;li&gt;CMM5 – MC1R (16q24)&lt;/li&gt;
&lt;li&gt;CMM6 – XRCC3 (14q32)&lt;/li&gt;
&lt;li&gt;CMM7 – mapped to chromosome 20q11&lt;/li&gt;
&lt;li&gt;CMM8 – MITF (3p13)&lt;/li&gt;
&lt;li&gt;CMM9 – TERT (5p15)&lt;/li&gt;
&lt;li&gt;CMM10 – POT1 (7q31)&lt;/li&gt;
&lt;/ul&gt;

&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/CDKN2A.jpg&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Prognosis.jpg&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Tx-strategies.jpg&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Approved-Tx.jpg&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/CIT.jpg&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Legend-CIT.jpg&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Stage-3-Tx.jpg&#34;
  &gt;


&lt;hr /&gt;


&lt;section data-noprocess data-shortcode-slide
  
      
      data-background-image=&#34;./Slides/Tx-Metastatic-Dz.jpg&#34;
  &gt;


&lt;hr /&gt;
</description>
    </item>
    
    <item>
      <title>Diagnosis and Initial Management of Melanoma</title>
      <link>/talk/medical_education_program_on_melanoma_management_melanoma-8-23-19/</link>
      <pubDate>Fri, 23 Aug 2019 08:00:00 +0000</pubDate>
      <guid>/talk/medical_education_program_on_melanoma_management_melanoma-8-23-19/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Melanoma</title>
      <link>/talk/harvard_derm_resident_lecture_melanoma-08-01-19/</link>
      <pubDate>Thu, 01 Aug 2019 07:00:00 +0000</pubDate>
      <guid>/talk/harvard_derm_resident_lecture_melanoma-08-01-19/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Cutaneous Oncology Board Preparation</title>
      <link>/talk/bidmc_board_prep-05-20-19/</link>
      <pubDate>Mon, 20 May 2019 15:00:00 +0000</pubDate>
      <guid>/talk/bidmc_board_prep-05-20-19/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Neoadjuvant PD-1 Blockade in Resectable Melanoma</title>
      <link>/talk/harvard_derm_resident_journal_club-03-25-19/</link>
      <pubDate>Mon, 25 Mar 2019 07:00:00 +0000</pubDate>
      <guid>/talk/harvard_derm_resident_journal_club-03-25-19/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Introduction to Melanoma</title>
      <link>/talk/harvard_derm_resident_lecture_melanoma-07-31-18/</link>
      <pubDate>Tue, 31 Jul 2018 07:00:00 +0000</pubDate>
      <guid>/talk/harvard_derm_resident_lecture_melanoma-07-31-18/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Introduction to Melanoma</title>
      <link>/talk/cumc_derm_lecture_melanoma-05-18-18/</link>
      <pubDate>Fri, 18 May 2018 11:00:00 +0000</pubDate>
      <guid>/talk/cumc_derm_lecture_melanoma-05-18-18/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Nivolumab as Adjuvant Therapy for Melanoma</title>
      <link>/talk/bidmc_journal_club_10-31-17/</link>
      <pubDate>Tue, 31 Oct 2017 08:00:00 +0000</pubDate>
      <guid>/talk/bidmc_journal_club_10-31-17/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Melanoma</title>
      <link>/talk/cumc_derm_lecture_melanoma-03-27-15/</link>
      <pubDate>Fri, 27 Mar 2015 09:00:00 +0000</pubDate>
      <guid>/talk/cumc_derm_lecture_melanoma-03-27-15/</guid>
      <description></description>
    </item>
    
  </channel>
</rss>
